Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1586

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 5
Chunk 1586
---

cash flow from operations. Further, there are no assurances that we will be successful in obtaining an adequate level of financing for
the development and commercialization of our other product candidates.

There are numerous risks and uncertainties
associated with the development of our NO delivery system and we are unable to estimate the amounts of increased capital outlays and operating
expenses associated with the completion of the research and development of our product candidates.

80

There are numerous risks and uncertainties
associated with the development of our NO delivery system and we are unable to estimate the amounts of increased capital outlays and
operating expenses associated with completing the research and development of our product candidates.

Our future capital requirements
will depend on many factors, including:

    ●
    the progress and costs of our preclinical studies, clinical trials and other research and development activities;
  
    ●
    the costs of commercializing the LungFit® system;
  
    ●
    the scope, prioritization and number of our clinical trials and other research and development programs;
  
    ●
    the costs and timing of obtaining certification or regulatory approval for our product candidates;
  
    ●
    the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
  
    ●
    the costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical quantities of our product candidates;
  
    ●
    the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally;
  
    ●
    the costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of our product candidates;
  
    ●
    the magnitude of our general and administrative expenses; and
  
    ●
    any cost that we may incur under current and future in-and-out-licensing arrangements relating to our product candidates.

Comparison between Fiscal Years Ended March 31,
2025 and March 31, 2024

Cash Flows

Below is a summary of the statements
of cash flows for the years ended March 31, 2025 and March 31, 2024.

    (in thousands) 
    For The Year Ended March 31, 2025  
    For The Year Ended March 31, 2024 

    Net cash provided by (used in): 

    Operating activities 
    $(38,218) 
    $(56,014)
  
    Investing activities 
    $14,905  
    $(12,235)